Vistin Pharma ASA (VISTN) - Total Liabilities
Based on the latest financial reports, Vistin Pharma ASA (VISTN) has total liabilities worth Nkr127.45 Million NOK (≈ $13.41 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore VISTN year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Vistin Pharma ASA - Total Liabilities Trend (2016–2024)
This chart illustrates how Vistin Pharma ASA's total liabilities have evolved over time, based on quarterly financial data. See Vistin Pharma ASA (VISTN) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Vistin Pharma ASA Competitors by Total Liabilities
The table below lists competitors of Vistin Pharma ASA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TTEC Holdings Inc
NASDAQ:TTEC
|
USA | $1.31 Billion |
|
AKA Brands Holding Corp
NYSE:AKA
|
USA | $303.27 Million |
|
Technical Olympic S.A
AT:OLYMP
|
Greece | €42.24 Million |
|
Eolus Vind AB (publ)
ST:EOLU-B
|
Sweden | Skr983.00 Million |
|
MIC Electronics Limited
NSE:MICEL
|
India | Rs1.37 Billion |
|
Micware Co., Ltd. American Depositary Shares
NASDAQ:MWC
|
USA | $16.06 Billion |
|
Pelican Acquisition Corporation Ordinary Shares
NASDAQ:PELI
|
USA | $583.17K |
|
Data Communications Management Ltd
TO:DCM
|
Canada | CA$321.00 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Vistin Pharma ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see VISTN company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vistin Pharma ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vistin Pharma ASA (2016–2024)
The table below shows the annual total liabilities of Vistin Pharma ASA from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Nkr75.42 Million ≈ $7.94 Million |
-6.46% |
| 2023-12-31 | Nkr80.63 Million ≈ $8.48 Million |
-39.81% |
| 2022-12-31 | Nkr133.95 Million ≈ $14.10 Million |
+133.93% |
| 2021-12-31 | Nkr57.26 Million ≈ $6.03 Million |
+15.65% |
| 2020-12-31 | Nkr49.51 Million ≈ $5.21 Million |
-45.45% |
| 2019-12-31 | Nkr90.77 Million ≈ $9.55 Million |
-39.97% |
| 2018-12-31 | Nkr151.21 Million ≈ $15.91 Million |
+35.50% |
| 2017-12-31 | Nkr111.59 Million ≈ $11.74 Million |
+20.11% |
| 2016-12-31 | Nkr92.91 Million ≈ $9.78 Million |
-- |
About Vistin Pharma ASA
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is based in Oslo, Norway.